StockData

Kamada vs Maravai LifeSciences

KMDA and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KMDA and MRVI compare

Kamada grew revenue faster over the last twelve months (13.2% versus −5.0% for Maravai LifeSciences).

Maravai LifeSciences scores higher on the StockData Score (7 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKMDAMRVI
Size and price
Market cap–$1.9B
Share price$8.11$7.40
Change, 1 year14.5%128%
Change, 5 years28.5%−82.2%
Beta (5Y)0.840.29
Employees393435
StockData Score
Total score57 (better)
Valuation score00
Growth score22
Performance score02 (better)
Health score33
Dividend score00
Valuation
P/S–9.2×
P/B–9.4×
FCF yield–−1.9%
Fair value–$2.74
Margin of safety–−170%
Growth
Revenue growth (TTM)13.2% (better)−5.0%
Revenue growth, 5Y average6.3% (better)−8.1%
EPS growth, 5Y average−1.6%–
Profitability
Gross margin40.8% (better)34.9%
Operating margin14.5% (better)−56.1%
Net margin–−37.1%
FCF margin–−17.2%
Return on equity–−32.9%
Return on invested capital–−32.4%
Financial health
Debt / equity–0.72
Net debt / EBITDA−0.54–
Interest coverage26.8× (better)−4.9×
Current ratio4.06 (better)4.05
Altman Z-score–4.57
Piotroski F-score–2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions8.6%55.5%
Held by insiders45.3%3.6%
Insider net buying, 12 months−$1.7M$115K (better)
Short interest, % of float0.53%5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.